Form 4: Ultragenyx Pharmaceutical Inc. Executive Acquires Shares and Options
SEC Form 4 Filing
Dennis Karl Huang, an executive at Ultragenyx Pharmaceutical Inc., reports acquisition of shares and stock options, along with the surrender of shares for tax obligations.
Summary
- On March 1, 2024, Dennis Karl Huang, EVP, Chief Technical Operations Officer of Ultragenyx Pharmaceutical Inc., acquired 17,800 shares of common stock through Restricted Stock Units (RSUs) and 957 shares through the conversion of performance stock units.
- Huang also acquired 31,400 stock options with an exercise price of $53.69, exercisable starting March 1, 2024.
- 470 shares were surrendered to the issuer to cover tax withholdings related to the vesting of RSUs at a price of $53.69.
- Following these transactions, Huang beneficially owns 83,002 shares of Ultragenyx Pharmaceutical Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing of executive stock transactions, indicating standard compensation practices. There's no explicit positive or negative information that would significantly sway investor sentiment.
Positives
- The acquisition of shares and options by an executive could be seen as a positive signal, indicating confidence in the company's future performance.
Negatives
- The surrender of shares to cover tax obligations could be interpreted as a need to liquidate some holdings, although it's a common practice.
Risks
- Executive stock transactions are subject to market fluctuations and company performance, which could impact the value of the holdings.
- Vesting schedules and performance conditions attached to RSUs and stock options introduce uncertainty regarding the actual realization of these benefits.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedules of the RSUs and stock options suggest a multi-year commitment by the executive.
Industry Context
Executive stock transactions are common in the pharmaceutical industry as part of compensation packages designed to align management interests with shareholder value. These transactions are closely watched by investors for insights into executive sentiment and company prospects.
Comparison to Industry Standards
- Executive compensation packages in the pharmaceutical industry often include a mix of salary, stock options, and restricted stock units.
- Vesting schedules for stock options and RSUs are typically structured over several years to incentivize long-term performance.
- Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize similar equity-based compensation strategies for their executives.
Stakeholder Impact
- The transactions could have a minor positive impact on shareholder sentiment if interpreted as a sign of executive confidence.
- Employees may view the executive's stock ownership as aligning management's interests with their own.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | Date of earliest transaction: Acquisition of shares and stock options, surrender of shares for tax obligations. |
| 03/01/2024 | Date of RSU vesting start: 1/4th of the underlying shares vest on each anniversary of the grant date. |
| 03/01/2024 | Date of stock option vesting start: 1/4th of the shares initially subject to the option shall vest on the Option Anniversary Date. |
| 03/05/2024 | Date of signature on the Form 4 filing. |
| 03/01/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.